BioSyent to Present at the LD Micro Main Event 2015 Investor Conference

TORONTO, ONTARIO--(Marketwired - Nov. 30, 2015) - BioSyent Inc. ("BioSyent") (TSX VENTURE:RX) is pleased to announce that CEO René Goehrum will be making a presentation at the LD Micro Main Event 2015 Investor Conference at 9am (PT) on December 3, 2015 at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Mr. Goehrum will provide an overview of the Company and its corporate activities.

The presentation will be webcast live at the following conference link: http://wsw.com/webcast/ldmicro9/bioyf. A replay of the webcast will be available for 365 days after the presentation date at the noted conference link or may be accessed by visiting the Investor Centre at the company's website, www.biosyent.com.

Mr. Goehrum will be available for 1:1 meetings on the day of his presentation. These meetings can be arranged through the conference organizers: http://www.ldmicro.com/p/main-event.html.

To view and listen to the CEO presentation on the Third Quarter 2015 Financial Results released November 11, 2015, please visit the following link: www.biosyent.com/q3-15/.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, hospital and international business units.

As of the date of this press release, the Company has 13,981,195 shares issued and outstanding.

For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.

The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.